Professeur Dr. Burçak YILMAZ

Intérêts médicaux

• Thérapies par radionucléides
• imagerie et compte rendu PET-CT et PET-IRM
• imagerie et compte rendu de médecine nucléaire conventionnelle (SPECT/CT, gamma-caméra)

CV

Formation

• 2018–Halen – Sağlık Bilimleri Üniversitesi – Doktora (Moleküler Onkoloji)
• 2012 – İstanbul Üniversitesi-Cerrahpaşa – Doktora (Nükleer Tıp)
• 2006 – İstanbul Üniversitesi-Cerrahpaşa – Yüksek Lisans (İngilizce Tıp)
• 2000 – Bahçeşehir Koleji – Okul Birinciliği

Expérience

• 2025–Günümüz – Biruni Üniversitesi Tıp Fakültesi Hastanesi – Doçent Doktor (Nükleer Tıp)
• 2023–2024 – Oregon Health and Science University, Nuclear Medicine Department – Postdoctoral Scholar
• 2022–2023 – Medipol Üniversitesi Bahçelievler Hastanesi – Doçent Doktor (Nükleer Tıp)
• 2020–2022 – Sağlık Bilimleri Üniversitesi Başakşehir Çam ve Sakura Şehir Hastanesi, Nükleer Tıp Kliniği – Doçent Doktor (Eğitim ve İdari Sorumlusu)
• 2020 – Sağlık Bilimleri Üniversitesi İstanbul EAH – Doçent Doktor (Nükleer Tıp)
• 2017 – University of Washington, Nuclear Medicine Department – Observer Doctor
• 2012–2020 – Sağlık Bilimleri Üniversitesi’ne bağlı EAH’ler (İstanbul) – Uzman Doktor (Nükleer Tıp)
• 2007–2012 – İstanbul Üniversitesi-Cerrahpaşa, Nükleer Tıp ABD – Tıpta Uzmanlık Öğrencisi

Langues

• İngilizce
• Almanca

Informations tarifaires

Appelez pour connaître les frais de consultation.

Adresses

Itinéraire

Publications scientifiques

Adhésions scientifiques

• Türkiye Nükleer Tıp Derneği

Publications

• Uluslararası Hakemli Dergilerde Yayımlanan Makaleler A1. Yılmaz B, Şahin S, Ergül N, Çolakoğlu Y, Baytekin HF, Sökmen D, Tuğcu V, Taşçı Aİ, Çermik TF.99mTc-PSMA targeted robot-assisted radioguided surgery during radical prostatectomy and extended lymph node dissection of prostate cancer patients.Ann Nucl Med. 2022 Apr 15. doi: 10.1007/s12149-022-01741-9. A2. Çermik TF, Ergül N, Yılmaz B, Mercanoğlu G.Tumor Imaging With 68Ga-DOTA-FAPI-04 PET/CT: Comparison With 18F-FDG PET/CT in 22 Different Cancer Types.Clin Nucl Med. 2022;47(4):e333-e339. doi: 10.1097/RLU.0000000000004073. A3. Ergül N, Yılmaz B, Cin M, Çermik TF.68Ga-DOTA-FAPI-04 PET/CT in Neuroendocrine Carcinoma of the Liver With Elevated AFP Level: Comparison With 18F-FDG PET/CT.Clin Nucl Med. 2022;47(1):e29-e31. doi: 10.1097/RLU.0000000000003811. A4. Aksu A, Vural Topuz Ö, Yilmaz B, Karahan Şen NP, Acar E, Çapa Kaya G.Prediction of early biochemical response after 177Lu-PSMA radioligand therapy with 68Ga-PSMA PET: A quantitative perspective.Nucl Med Commun. 2022;43(4):468-474. doi: 10.1097/MNM.0000000000001539. A5. Aksu A, Vural Topuz Ö, Yılmaz G, Çapa Kaya G, Yılmaz B.Dual time point imaging of staging PSMA PET/CT quantification: Spread and radiomic analyses.Ann Nucl Med. 2022;36(3):310-318. doi: 10.1007/s12149-021-01705-5. A6. Aksu A, Bozkurt K, Yilmaz B.Tracheitis Diagnosed With 68Ga-PSMA PET/CT in a Patient With COVID-19.Clin Nucl Med. 2022. doi: 10.1097/RLU.0000000000004288. A7. Aksu A, Şin C, Yilmaz B.Adult Tiger Man: A Case of Dermatomyositis Associated With Thymoma.Clin Nucl Med. 2022;47(6):e448-e449. doi: 10.1097/RLU.0000000000004154. A8. Yilmaz B, Nisli S, Ergul N, Gürsu RU, Açikgöz Ö, Çermik TF.Effect of external cooling on Lu-177 PSMA uptake for parotid glands.J Nucl Med. 2019;60(10):1388-1393. doi: 10.2967/jnumed.119.226449. A9. Yilmaz B, Dag Z, Ergul N, Çermik TF.The ability of pretreatment F-18 FDG PET/CT metabolic parameters for predicting axillary lymph node and distant metastasis and overall survival.Nucl Med Commun. 2019;40(11):1112-1121. doi: 10.1097/MNM.0000000000001085. A10. Yilmaz B, Turkay R, Colakoglu Y, Baytekin HF, Ergül N, Sahin S, Tugcu V, İnci E, Taşçi AI, Çermik TF.Comparison of preoperative locoregional Ga-68 PSMA-11 PET/CT and mp-MRI results with postoperative histopathology of prostate cancer.Prostate. 2019;79(9):1007-1017. doi: 10.1002/pros.23812. A11. Yilmaz B, Dağ Z, Ergül N, Çermik TF.The efficacy of pretreatment and post-treatment 18F-FDG PET/CT metabolic parameters in locally advanced squamous cell cervical cancer.Nucl Med Commun. 2019;40(3):219-227. doi: 10.1097/MNM.0000000000000969. A12. Akaike G, Itani M, Shah HAJ, Yilmaz Gunes B, Assaker R, Behnia F.PET/CT in the Diagnosis and Workup of Sarcoidosis: Focus on Atypical Manifestations.Radiographics. 2018;38(5):1536-1549. doi: 10.1148/rg.2018180053. A13. Ergül N, Yilmaz Güneş B, Yücetaş U, Toktaş MG, Çermik TF.68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.Clin Nucl Med. 2018;43(12):422-427. doi: 10.1097/RLU.0000000000002289. A14. Dağ Z, Yilmaz B, Kutluhan DA, Unluer AD, Özkurt H, Kizilkaya HO, Arslan D.Comparison of prognostic value of F-18 FDG PET/CT metabolic parameters and MRI findings in locally advanced cervical cancer.Brachytherapy. 2019;18(2):154-162. doi: 10.1016/j.brachy.2018.11.005. A15. Sağer MS, Hatipoğlu E, Güneş B, Asa S, Uslu L, Sönmezoğlu K.Comparison of day 3 and day 5 thyroglobulin results after thyrogen injection in differentiated thyroid cancer patients.Ther Adv Endocrinol Metab. 2018;9(6):177-183. doi: 10.1177/2042018818770108. A16. Yilmaz Güneş B, Önsel Ç, Sönmezoğlu K, Özaras R, Halac M, Tabak OF, Sağer MS, Mete B, Sayman B, Kanmaz B.Diagnostic value of F-18 FDG PET/CT in spondylodiscitis: Is dual time point imaging worthwhile?Diagn Microbiol Infect Dis. 2016;85(3):381-385. doi: 10.1016/j.diagmicrobio.2016.03.021. A17. Yilmaz B, Arslan H, Gündoğan C, Güneş MN, Çermik TF.False-Positive 68Ga-DOTATATE PET/CT in Active Chronic Prostatitis.Clin Nucl Med. 2019;44(8):499-500. doi: 10.1097/RLU.0000000000002594. A18. Gündoğan C, Yardımcı AH, Yilmaz Güneş B, Çermik TF.Subacute Venous Infarct Mimicking Cerebral Metastasis in 18F-FDG PET/CT.Clin Nucl Med. 2019;44(2):120-122. doi: 10.1097/RLU.0000000000002391. A19. Bulut N, Yilmaz B.Misleading 18F-FDG PET/CT finding caused by chronic HIV infection in a patient with gastric carcinoma.Int J STD AIDS. 2018;29(1):96-98. doi: 10.1177/0956462417724709. A20. Itani M, Yilmaz Güneş B, Akaike G, Behnia F.Lacrimal gland uptake on F-18 florbetapir amyloid PET scan.Radiol Case Rep. 2017;13(1):265-268. doi: 10.1016/j.radcr.2017.10.029. A21. Bulut N, Dağistanli S, Yilmaz B, Atay FO.Surgical approach to anorectal melanoma with PET-CT staging: A case report.Surg J. 2017;3(4):177-180. doi: 10.1055/s-0037-1608902. A22. Yilmaz Güneş B, Özvar FH, Demirci E, Özkurt H, Baytekin HF, Kabuli H.Parasitic infestation mimicking hepatic metastasis in a patient with breast carcinoma.Breast J. 2017;23(4):468-470. doi: 10.1111/tbj.12771. A23. Yilmaz Güneş B, Akbayir Ö, Demirci E, Ozaydin İ.Clinical, pathological and 18F-FDG PET/CT findings in synchronous primary vaginal and endometrial cancers.Hell J Nucl Med. 2016;19(2):170-172. doi: 10.1967/s002449910374. A24. Arslantaş E, Ayçiçek A, Akıcı F, Özkara S, Yılmaz B, Özdemir N, Bayram C.Comparison of bone marrow biopsy and FDG-PET for assessment of bone marrow infiltration in children with Hodgkin’s lymphoma.Nuklearmedizin. 2023;62(1):20-26. doi: 10.1055/a-1972-9292. A25. Vural Topuz Ö, Omak Ö, Yılmaz B.Primary isolated breast lymphoma presenting as primary breast cancer with 18F-FDG PET/CT.Mol Imaging Radionucl Ther. 2023;32(1):83-86. doi: 10.4274/mirt.galenos.2022.58671. A26. Chalker C, Yilmaz B, Trone K, Parecki G, Chen A, Lim JY, Mallak N, Sokolova AO.Use of PSMA PET/CT to detect prostate cancer metastatic to a preexisting thyroid nodule.NPJ Precis Oncol. 2024;8(1):132. doi: 10.1038/s41698-024-00619-5. A27. Mallak N, Yilmaz B, Meyer C, Winters C, Mench A, Jha AK, Prasad V, Mittra E.Theranostics in Neuroendocrine Tumors: Updates and Emerging Technologies.Curr Probl Cancer. 2024;52:101129. doi: 10.1016/j.currproblcancer.2024.101129. Yerli Hakemli Dergilerde Yayımlanan Makaleler B1. Yilmaz Güneş B, Erez Ö, Gündoğan C, Ergül N.Evaluation of external dose rate measurements during and after F-18 FDG PET/CT imaging.Istanbul Med J. 2019;20(3):188-192. doi: 10.4274/imj.galenos.2018.85698. B2. Yilmaz B, Gündoğan C.Effect of transarterial Y-90 microsphere treatment on biochemical parameters in liver tumors.Istanbul Med J. 2019;20(5):436-440. doi: 10.4274/imj.galenos.2019.24444. B3. Dağ S, Doğan AK, Canaz E, Arslan ND, Yilmaz B.Diagnostic accuracy of preoperative metabolic 18F-FDG PET/CT parameters in endometrial cancer.Cam and Sakura Med J. 2021;1(1):14-23. B4. Arslan ND, Dağ S, Doğan AK, Gurcay N, Ozkurt H, Yilmaz B.Regression of hypermetabolic splenic granulomata mimicking metastases.Cam and Sakura Med J. 2021;1(1):37-42. B5. Gündoğan C, Ergül N, Serin H, Beyhan E, Yılmaz B, Çermik TF.Prognostic role of interleukin-23 in prostate adenocarcinoma.IMJ. 2021;22:320-325. B6. Akgün E, Gür F, Yılmaz B.Diffuse bone marrow involvement of Langerhans cell histiocytosis detected with F-18 FDG PET/CT.Cam and Sakura Med J. 2022;2(2):80-81.